GO
Loading...

GlaxoSmithKline PLC

More

  • Ebola vaccine seems safe in first-stage testing Wednesday, 26 Nov 2014 | 5:00 PM ET

    The vaccine is designed to spur the immune system's production of anti-Ebola antibodies, and people developed them within four weeks of getting the shots at the National Institutes of Health. Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases, whose employees led the work. Earlier this month, Fauci told Congress this...

  • WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...

  • Merck, Iowa firm sign Ebola vaccine licensing deal Monday, 24 Nov 2014 | 1:28 PM ET

    TRENTON, N.J.— Merck& Co., a top creator and seller of vaccines, has joined the fight against Ebola, the often-fatal hemorrhagic virus that's been ravaging parts of West Africa for months. The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of...

  • Nov 24- BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million, betting on a drug that has potential to become the first approved treatment for a rare muscle disorder. "Though the asset has risk given the clinical history, we believe the payoff for BioMarin could be substantial given the unmet need...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...

  • DAKAR/ BRUSSELS, Nov 14- Medecins Sans Frontiers "wasted time" by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters. The group's response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization.

  • LONDON, Nov 13- Apollo Global Management is planning to bid for all GlaxoSmithKline's mature drugs, joining an auction expected to value the business at more than $3 billion, according to four people familiar with the process. GSK, Britain's biggest drugmaker, is looking to divest its mature prescription medicine products sold in North America and western...

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros in Ebola research, with the lion's share going to the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and the...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros into Ebola research, with the lion's share going to fast-track the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and...

  • PARIS, Oct 28- French drugmaker Sanofi said sales growth at its leading business of diabetes treatments would stall next year due to tough competition on prices in the United States, sending its shares down more than 8 percent on Tuesday. The drop in Sanofi's shares was the steepest in five years and wiped 9.2 billion euros off the company's market value.

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • Drugmakers double down on Ebola vaccines, treatments Monday, 27 Oct 2014 | 7:31 AM ET
    People participate in a march, organized by New York’s West African community, to end Ebola, Oct. 24, 2014, in New York.

    Drugmakers are racing to develop vaccines and drugs to address Ebola, betting that governments and aid groups will foot the bill.

  • US stocks and sectors to watch after NY Ebola case Friday, 24 Oct 2014 | 4:45 AM ET
    Traders on the floor of the New York Stock Exchange.

    Global equity strategists pick out U.S. sectors and stocks that could be affected in Friday's trading session on the back of the NY Ebola case.

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or claims arising from the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate...

  • *Topic expected to be discussed at Geneva vaccines meeting. LONDON/ GENEVA, Oct 23- Drugmakers are looking for some kind of indemnity from governments or multilateral agencies for the widespread emergency use of new Ebola vaccines in Africa. While the issue will not delay the industry's ongoing work to accelerate production and clinical testing of three...

  • Wall Street fell as Boeing Co and Biogen Idec tumbled after their results disappointed investors, the two biggest drags on the S&P 500.. The retreat on Wall Street pulled MSCI's gauge of global equity performance lower, but European stocks closed higher, largely driven by earnings. GlaxoSmithKline rose 2.6 percent in London after saying it expects an Ebola...